NHF Filled Only 65 Percent of Drug Orders as J$4.5 Billion Debt Crippled Jamaica’s Public Health Supply Chain

A performance audit by the Auditor General of Jamaica has found that the National Health Fund, the statutory body responsible for supplying medicines to the country’s public hospitals and health centres, delivered fewer than two in three drug orders over a five-year period — a failure rooted in a mounting receivables crisis that saw the Ministry of Health accumulate J$4.5 billion in unpaid obligations. For the millions of Jamaicans who depend on the public health system, the consequences have been stocked-out shelves, interrupted treatment and a benefits programme quietly drained to cover the shortfall.

When a patient walks into a public health centre in Jamaica and is told the medication they need is out of stock, it rarely makes headlines. It is, for too many Jamaicans, simply a familiar frustration — a blank shelf, a shrug from a nurse, a journey home empty-handed. But a performance audit by the Auditor General of Jamaica has now put hard numbers to what residents have long experienced, and those numbers reveal a supply chain failure of serious proportions at the National Health Fund.

The audit, which examined the NHF’s pharmaceutical division across fiscal years 2011/12 through 2015/16 — with additional data drawn from 2016/17 — found that the agency responsible for procuring, warehousing and distributing drugs and medical sundries to Jamaica’s public healthcare network was, on average, filling only 65.2 percent of orders placed by the facilities it was mandated to serve. That figure represents systemic underperformance, not a temporary blip, and it worsened materially over the review period: fulfillment stood at 79.1 percent in FY2011/12 and plummeted to a low of 52.3 percent by FY2015/16 before partially recovering to 66.6 percent in FY2016/17.

The NHF was established under statute in 2003 and assumed pharmaceutical procurement responsibilities from Health Corporation Limited following a 2011 amendment to the NHF Act. Its mandate aligns with Jamaica’s Vision 2030 National Development Plan, which commits to quality public health delivery as a pillar of national development. The distance between that mandate and what the audit found is considerable.

For the segment of drugs classified as critical pharmaceuticals — the medicines most urgently required in emergency and chronic care settings — the NHF achieved a fulfillment rate of only 73 percent in FY2015/16, against a 90 percent service level target. By FY2016/17 that figure had improved to 80 percent, still ten percentage points below where it needed to be. Chronic illness drugs, which cover conditions including diabetes, hypertension and cardiovascular disease — ailments disproportionately prevalent in Jamaica’s aging population — also fell short, reaching only 75 percent fulfillment in FY2015/16 and 84 percent in FY2016/17, both below the same 90 percent benchmark.

The human cost of these statistics is not abstracted. Public hospitals and health centres serve Jamaicans who cannot afford private care. When medicines are unavailable, those patients go without, return repeatedly to already overburdened facilities, or purchase drugs out-of-pocket at private pharmacies — a cost many cannot absorb. The audit’s mandate may have been performance-focused, but its findings describe a service delivery failure with direct consequences for some of the country’s most economically vulnerable households.

The Auditor General identified the root cause with uncomfortable clarity. The NHF’s operational collapse was driven overwhelmingly by a financial crisis traceable to its own institutional environment. Trade receivables — money owed to the NHF by the facilities and agencies it supplies — grew by 267.5 percent over the review period, rising from J$1.69 billion in FY2011/12 to J$4.5 billion by FY2016/17. Of that total, the Ministry of Health itself accounted for 94 percent of all outstanding balances. The very government ministry responsible for overseeing public health was, simultaneously, the single largest debtor threatening the supply chain that keeps public health facilities operational.

The aging of that debt compounded the damage. The average number of days that receivables remained outstanding climbed from 129 days in FY2011/12 to 222 days by FY2016/17 — meaning the NHF was, by the final year of the review, waiting more than seven months on average to be paid for drugs already delivered. Of the Ministry of Health’s outstanding balance, 67.6 percent — approximately J$2.9 billion — had been overdue for more than 90 days. No firm timeline had been established for reducing the backlog, and the Auditor General found no systematic mechanism in place to compel resolution.

The financial pressure this created rippled outward in predictable and damaging ways. Unable to collect what it was owed, the NHF struggled to pay its own suppliers on time. The audit found that the NHF failed to meet supplier payment deadlines in 95.8 percent of cases between FY2013/14 and FY2016/17. Suppliers responded by placing the NHF on credit holds — a standard commercial response that, in this context, meant pharmaceuticals stopped being shipped. In FY2015/16 alone, 56 separate instances were recorded in which drugs were unavailable because payment delays had triggered a credit hold. Across the audit period, 582 individual stock-out incidents were documented, spanning general drugs, which accounted for 36 percent of cases, cardiac drugs at 13 percent, antibiotics at 13 percent and anti-psychotic medications at 11 percent. That last category carries particular weight given the longstanding pressures on Jamaica’s mental health infrastructure and the fragile situation of patients dependent on consistent medication regimens.

To keep operations running in the face of mounting unpaid receivables, the NHF made a financial decision the Auditor General flagged with considerable concern. Between FY2011/12 and FY2016/17, the agency transferred a cumulative J$2.4 billion from its Benefits Division to cover pharmaceutical division obligations. The Benefits Division funds health insurance contributions and drug subsidies for registered NHF cardholders — many of them elderly or chronically ill Jamaicans who depend on those benefits directly. Diverting funds from one vulnerable population’s programme to cover deficits created by a separate institutional failure raises transparent questions about the long-term sustainability of the benefits programme itself, and about the governance structures that allowed such transfers to continue across multiple fiscal years without resolution.

The situation deteriorated to the point that in FY2016/17 the NHF was forced to write off J$2.0 billion in Ministry of Health receivables — debt deemed unrecoverable. This is public money effectively extinguished by institutional dysfunction: the Ministry of Health accumulated obligations it could not service, the NHF could not compel payment, and the result was a J$2 billion loss absorbed by an agency that was simultaneously struggling to keep drug shelves stocked.

Inventory management inside the NHF’s warehouse operation also deteriorated across the review period. Accuracy levels — a measure of how well physical stock matches recorded inventory — fell from 87.3 percent in FY2013/14, when 252 items showed variances, to 73.2 percent in FY2016/17, when 320 items showed variances, 183 of which were negative. Negative inventory variances mean physical stock is lower than what records indicate — a condition that creates false confidence in availability and undermines procurement decisions. The audit found that ad hoc stock counts, which function as a check on inventory accuracy, occurred only twice during the entire review period. The infrequency of these checks left the warehouse operating with data that did not reliably reflect reality.

The Auditor General also identified weaknesses in how demand was being forecast. Without a rigorous, systematic approach to predicting what quantities of which drugs would be needed and when, procurement decisions were made on incomplete assumptions. Combined with external factors — global drug shortages, customs clearance delays, and exposure to foreign exchange fluctuations that increase the cost of imported pharmaceuticals — the absence of strong forecasting methodology left the supply chain without adequate buffers against disruption.

Management’s response to the audit included acknowledgment that performance tracking indicators had been introduced and that plans were underway to upgrade the warehouse management system. The Auditor General assessed these initiatives but found them insufficient to address the foundational financial and operational problems identified. Tracking performance more carefully does not, by itself, resolve a J$4.5 billion receivables problem or a pattern of supplier payment failures across nearly all transactions. The audit’s conclusion was that the supply chain for Jamaica’s public health system remained, at the close of the review period, in a persistently fragile state.

The implications extend beyond the health sector alone. Public pharmacies, health centres and hospitals are distributed across Jamaica’s parishes, serving communities in both urban and rural settings. When supply chains fail, the residents of rural communities — already at greater distance from private alternatives — bear a disproportionate share of the burden. For families managing chronic conditions, for communities with limited transport access to private pharmacies, for patients following treatment plans that depend on consistent medication availability, a 65 percent fulfillment rate is not an administrative statistic. It is the reality of care they are receiving.

What the audit ultimately demands is a structural response rather than a procedural one. The Ministry of Health’s position as both the NHF’s primary customer and its dominant debtor creates an inherent governance tension that administrative improvements alone cannot resolve. The Auditor General called on the NHF to secure a permanent, enforceable resolution to the receivables problem — not a continuation of ad hoc arrangements — and to implement substantially stronger inventory controls. Until the financial relationship between the NHF and the Ministry of Health is placed on a sustainable footing, with binding repayment timelines and accountability mechanisms that carry real consequence, the supply chain will remain exposed to the same cycle of credit holds, stock-outs and benefits fund diversions that this audit has now placed on the public record. Any credible commitment to improving healthcare delivery in Jamaica’s public system must begin with resolving that foundational dysfunction.

Jamaica Accountability Watch is an independent editorial series by Jamaica Homes News examining what government audit reports reveal about the management of public money. Source: Auditor General’s Department of Jamaica.

Follow Jamaica Homes on Youtube @jamaicahomes and Instagram @jamaica_homes and on Facebook @jamaicahomes Send us a message or email us at onlinefeedback@jamaica-homes.com or editor@jamaica-homes.com